View Poll Results: Did you buy shares ?

1110. You may not vote on this poll
  • Yes, I'm acting now !

    694 62.52%
  • No

    416 37.48%
  1. Superfly_FR's Avatar
    The Blackberry design team introduced several elements including hardware, with antenna technologies being one of the major contributions from the Blackberry team according to ZTE.

    The antenna element is most likely Paratek technology and that is definitely BlackBerry.
    !important! Would be another milestone in IP licensing ...

    Sorry guys, again in my rehab' period (soooo gooood).
    Yet, I catch the news, and I like it !

    The BBRY Café.  [Formerly: I support BBRY and I buy shares]-img_20150728_205830.png

    The BBRY Café.  [Formerly: I support BBRY and I buy shares]-img_20150728_234930.png

    SF, in holidays !

    Posted via CB10
    07-28-15 05:56 PM
  2. JonCBK's Avatar
    Well that was nice that we got back some losses. Still way down for the month. But at least back into some normal fluctuation.

    I like the optionality with the cash, patents, skills and security brand name. I can't sell a company like that with its stock at sub $4 billion market cap. Ready for a turn around. Hopefully by the end of the year. But I do think that it won't be because of BBRY smartphones. Best to hope for is that it becomes a profitable niche product sold to governments, keyboard users, security focused consumers (super small niche) and maybe a few markets on brand name.

    Darn next quarter is so far away. I'm really curious how the cash flow will hold up for the rest of the year.
    07-28-15 06:11 PM
  3. BanffMoose's Avatar
    I dont think the US gov't wants a repeat of this below.
    Data hacked from U.S. government dates back to 1985: U.S. official | Reuters

    So the selection process, will have security as a major requirement. And Blackberry has all the pieces to answer this requirement. Watchdox at the file level, NOC during transport , and Certicom Encryption for the cloud. And at the device level, U.S. Department of Defense (DoD) has approved the use of derived Public Key Infrastructure (PKI) credentials on BlackBerry OS and BlackBerry 10 smartphones just a few days ago. All of those would seem to tie together in helping Allscipt and Nanthealth answer the needs of Pentagon.

    I believe tomorrow's presentation by Watchdox could be aimed at those decision makers who are still on the sidelines. Here's to hoping Allscripts win.
    The major caveat here, and this may point to a future BlackBerry acquisition, is that BlackBerry currently has no footprint on the desktop. Virtually all the recent data leaks have been from desktop/laptop or server penetrations or lost unencrypted harddrives. We're still probably a few years away from phones/tablets overtaking laptops and PCs.

    I'm on record that BB should put the toolbelt on all future devices. The touchpad is essentially a mouse. Update RDP clients and Citrix client apps to recognize the touchpad as a mouse, add options to temporarily repurpose the four toolbelt keys to act like mouse buttons when in "RDP/Citrix-mode", and you have an ultrabook that fits in your pocket (especially for PKB devices like the Passport and Classic)! Security is handled by the RDP/Citrix server and BlackBerry doesn't have to worry about making a desktop client. Just use Windows! If only they did this in 2012/2013 when developing BB10! How do we ask BlackBerry to do this?
    07-28-15 06:23 PM
  4. huwit's Avatar
    the passport pkb is a very nice alternative to the trackpad imo
    bungaboy, bbjdog, 3MIKE and 1 others like this.
    07-28-15 06:39 PM
  5. bbjdog's Avatar
    I was bored and went on Stock Twits, typed in BBRY and this is the first post I see.

    "@hassancharania: $BBRY @JohnLBair1 my passport just came in last night i cant put it down excellent phone." still trying to figure it out?

    Welcome to the Passport nation Stevemed!
    07-28-15 07:57 PM
  6. Corbu's Avatar
    BlackBerry Ltd shares jump most in six months on Morgan Stanley upgrade | Financial Post

    For this:

    In an interview last week, Chen said he’s still early into his turnaround.

    “I know there’s a lot of impatience out there right now, if you look at our stock price, you know it’s very impatient,” he said. “People need to be patient. It’s the right thing. It’s the right market.”
    07-28-15 08:24 PM
  7. Corbu's Avatar
    07-28-15 08:27 PM
  8. Corbu's Avatar
    07-28-15 08:28 PM
  9. Corbu's Avatar
    07-28-15 08:40 PM
  10. Corbu's Avatar
    07-28-15 08:50 PM
  11. BanffMoose's Avatar
    the passport pkb is a very nice alternative to the trackpad imo
    It is. But my point is to add a functional mouse along with left/right mouse buttons.

    With BB10, you can hook up a keyboard, mouse and monitor to your phone and log into your work/home computer via RDP or Citrix and have a fully functional Windows environment to work in. If you needed to go on the road, you can still access your work/home computer via RDP or Citrix but your experience is diminished because you don't have a mouse. The touchscreen can only do so much. You can't bring up contextual menus via a right mouse click. You don't have precise mouse control. Certain programs have slide controls, or drop down menus that require scrolling. There's probably more functions that require a real mouse.

    If BlackBerry invested a little bit of time to write an API to access/remap the toolbelt, RDP/Citrix app developers can give us that functional mouse! We would have keyboard, screen and MOUSE on a phone. BlackBerry can attack the ultrabook/tablet market! Best part is that BlackBerry doesn't have to recreate a desktop environment or get app developers. Tap into the Windows desktop/server ecosystem that is already available via RDP and Citrix! We'd have a fully functional MOBILE WINDOWS computer! We don't need to wait for Windows 10's universal apps. We'd have a secure, IT-managed Windows environment! Home users can set their Windows XP and higher computers up for RDP access and be able to use it for home as well!

    I don't think I'm missing anything critical here. Just a mouse on my phone!
    La Emperor, huwit, awindsr and 4 others like this.
    07-28-15 08:50 PM
  12. Corbu's Avatar
    Guys, we almost forgot our customary Amber fix to celebrate the "good" news from MS...

    07-28-15 09:58 PM
  13. DaSchwantz's Avatar
    Chen said the value of the company may not be seen for 12-18mths. AFAIK he reiterated his 600M for fiscal 2016 (now includes licencing / IP deals). MS is saying they have 3.50 in cash and 3.50 with a 4x multiple of software not including licensing deals. So they give no value to IP. They are building cash. So this in an admission that $7 is the lowest the SP is worth at current fundamentals and to me assumes no growth, but no decline in growth, no hardware, no BBM, no growth in qnx auto as that has not been proven yet (but will soon), no service fees as that will go to zero.

    Posted via CB10
    Yet Faucette complains that licensing the IP brings the resale value down....from zero, lol.

    Posted via CB10
    07-29-15 01:11 AM
  14. Bacon Munchers's Avatar
    The security pilage continues:

    Didn't Telefonica get a load of funds from the canuck government to purchase BlackBerry phones back in April 2013? What's up with this?
    rarsen and zyben like this.
    07-29-15 02:10 AM
  15. BACK-2-BLACK's Avatar
    How an Underwhelming BlackBerry Upgrade Rocks Shares Higher
    Posted by Jon C. Ogg

    "Whenever investors see a big stock pop higher on an analyst upgrade, they generally think that the rating means the stock is now a screaming buy or something close to it. But what about when an analyst upgrade just implies that a stock is now just no longer in the screaming sell category? This is the case for BlackBerry Ltd. (NASDAQ: BBRY) on Tuesday.

    With the well-known and highly visible struggling handset and operating system-makers stock performance in recent years, it turns out that investors might just have BlackBerry valued at a point where anything but bad news is treated far better than good news.

    BlackBerry shares were upgraded at Morgan Stanley on Tuesday to Equal Weight from Underweight. Here is the kicker BlackBerrys mere $7.00 price target was maintained versus the closing price of $7.28 on Monday. So what are investors supposed to think here? Morgan Stanley did remove that equivalent rating of Sell but still set a price valuation that is under the share price and shares were up 6% at $7.72 in mid-Tuesday trading.

    Several things were driving this odd reaction. One is that BlackBerry shares have been down handily by one-third of their value in the last couple of months to a new 52-week low. Morgan Stanley also cited a strong cash balance on the books that could be made even better if it has more layoffs or if it chooses to deploy its capital resources differently.

    Another driving force is that Morgan Stanley had been one of the biggest bears in BlackBerry. The report was not even all that praising. Morgan Stanley does not see improving business fundamentals, nor does it see a yet-successful software strategy.

    A large short interest is also contributing to BlackBerrys gains here. The short interest in mid-July was shown to be 105.16 million shares. That is higher than the end of June and was over 10 days to cover. It was even the highest short interest since the first 2015 short interest report in January.

    This may have been one of those perfect storms for investors. A high short interest in an oversold stock, removing a long-time bearish rating, and a climate where investors want a shot of catching a serious recovery can be powerful. This is one of those rare instances where you just know that investors are looking to grab hold of any good news that they can find.

    BlackBerrys $7.72 share price in mid-afternoon trading on Tuesday compares with a consensus price target of $8.81 and with a 52-week range of $7.15 to $12.63."
    awindsr, jxnb, 3MIKE and 1 others like this.
    07-29-15 06:50 AM
  16. Shanerredflag's Avatar
    Not new but nice to see folks talking:

    Classically Posted.
    07-29-15 09:07 AM
  17. BACK-2-BLACK's Avatar

    Will this be the start..... of the Jetson's car?

    Lexus will officially unveil its hoverboard on August 5th
    Posted on July 29, 2015 by Mariella Moon

    On August 5th, Lexus will finally reveal its hoverboard, which has been in development for the past 18+ months, to the public. Let that sink in for a bit: Lexus has created a working hoverboard in 2015, the year Marty and Doc Brown jumped to in Back to the Future...! Unfortunately, we don't know if you'd be able to buy one before October 21st -- or at all, really -- but even if it does become available for purchase in the next few months, you can't ride it to a B2F anniversary screening. See, it can only levitate over metallic surfaces, so it's pretty much useless in most places. That's about the extent of what we know about the device, though Lexus is bound to divulge more info during the event.

    snejpa and zyben like this.
    07-29-15 09:25 AM
  18. audio_Rx's Avatar
    Any chance the price will come down under $10?

    Posted via CB10
    07-29-15 09:39 AM
  19. bungaboy's Avatar
    Any chance the price will come down under $10?

    Posted via CB10
    In CAD on TSX? . . . yes, given this highly manipulated stock.

    Better to ask what analcyst Fawcette has for plans.
    3MIKE, morganplus8, sidhuk and 7 others like this.
    07-29-15 10:17 AM
  20. Corbu's Avatar

    The BBRY Café.  [Formerly: I support BBRY and I buy shares]-mc_0728155.jpg

    Market Bell Ceremonies - NASDAQ OMX

    A path to conquering cancer: NantKwest CEO

    NantKwest Gives Biotech Another Big IPO - WSJ

    These days, a biotech company doesn’t need an approved drug to be worth several billion dollars.

    The latest example of that is NantKwest Inc.: Its shares surged 39% on Tuesday, the first day of trading following an initial public offering that valued the company at $2.6 billion.

    It was the highest ever IPO valuation for a biotech company with no approved drugs, according to Renaissance Capital, an IPO research firm. NantKwest is just now finishing up the first phase of clinical trials for a treatment targeting cancer and infectious diseases.

    The share-price gain was notable but not anomalous in a market that is looking frothy to some market watchers. Last year, newly issued shares in companies that were just finishing preclinical or Phase 1 trials at the time of their IPOs rose 29% on average on their first day of trading, compared with a 15% climb for all biotech debuts in 2014. That is despite the fact that most experimental drugs fail, although some prove big breakthroughs.

    To some skeptics, the idea of multibillion-dollar valuations for drug companies with no products fits somewhere in the pantheon of behavior that includes buying Internet companies based on the number of eyeballs they draw. But fund managers have been emboldened by the success of several drugs and treatments that have gone from experimental to blockbusters, with share prices soaring in the process. A merger boom in the health-care industry also has bolstered returns.

    Investors are turning to biotech stocks in part because they expect paltry returns from safer investments amid tepid global growth.

    Interest rates continue to languish near zero in developed markets world-wide, and many investors see only modest gains in broad stock indexes in the next several years.

    In December, Juno Therapeutics Inc., an early-stage biotech company that is developing cancer treatments using the human body’s own immune system, netted a market valuation of about $1.9 billion at its IPO. Shares rose 46% in their first day of trading. Since the IPO, shares of Juno have doubled in value.

    But investors in Avalanche Biotechnologies Inc. experienced the opposite: The company’s shares fell 56% one day in June on investor concern about the strength of some midstage trial results.

    “I’m most concerned about companies that are preclinical, Phase 1, or even early Phase 2 that are now getting pretty robust valuations, at times well above $1 billion,” said Marshall Gordon, senior health-care analyst at ClearBridge Investments. A few years ago, these types of companies would usually have been valued at less than $500 million at the time of their IPOs, he argued.

    Investors aren’t holding back: In the first half of this year, $6.2 billion poured into mutual funds and exchange-traded funds with the word “biotechnology” in their name, according to Morningstar.

    That compares with net inflows of $3.5 billion for all of 2014. The Nasdaq Biotechnology Index has risen more than 26% in the year to date, compared with a 1.7% rise for the S&P 500.

    Before receiving approval, a drug or treatment must undergo several phases of clinical trials. Phase 1 involves testing the drug on a relatively small patient group to evaluate its safety. In Phase 2, a larger group is given the treatment, and the effectiveness of the drug is evaluated. By Phase 3, even more patients are given the treatment, which is compared with other commonly used treatments for the same affliction.

    According to the U.S. Food and Drug Administration, while about 70% of drugs move on from Phase 1, only one-third progress beyond Phase 2. Even fewer are ultimately approved. And while Phase 1 studies typically take several months, subsequent trials can take several years.

    NantKwest is wrapping up Phase 1 trials on using natural killer cells in the immune system to target cancer and infectious diseases.

    “It’s not a short track record,” said Dr. Patrick Soon-Shiong, chief executive of the company.

    Dr. Soon-Shiong is credited with inventing the cancer drug Abraxane. In 2010, Celgene Corp. acquired Abraxis BioScience Inc., maker of Abraxane, for $2.9 billion. Dr. Soon-Shiong, who was Abraxis’s executive chairman at the time, owned about 82% of the company’s shares outstanding. Abraxane had global sales of $848.2 million last year, up from $648.9 million in 2013.

    Among the investors in NantKwest is drug maker Celgene and funds managed by Franklin Templeton, according to the company’s prospectus. Investors said these two established names added legitimacy to the offering. Its shares priced above the range expected by its advisers, and heavy demand led NantKwest to expand the size of its IPO.

    David Miller, portfolio manager of Alpine BioVentures, a Seattle-based fund that makes both private and public investments, said some companies’ shares warrant higher-than-average valuations. He cited the potential revenue growth available for biotech companies, the pricing power for the treatments which they are developing and how drugs are receiving approval more quickly than in the past. The Food and Drug Administration approved 41 novel drugs in 2014, compared with an average of 25 annually from 2005 to 2013, according to the agency.

    Still, the risks are high, even as more early-stage biotech companies are lining up to go public. “We expect this pace [of biotech IPOs] to continue,” said Jim Cooney, head of health-care equity capital markets at Bank of America Merrill Lynch, which led the NantKwest IPO.

    “Biotech investing is tough because it’s easy to get emotional,” Mr. Miller said. “It’s easy to get excited about curing cancer or multiple sclerosis or Alzheimer’s. But most of these drugs fail.”
    lech31, La Emperor, 3MIKE and 13 others like this.
    07-29-15 10:27 AM
  21. La Emperor's Avatar
    OT ??? :Security . CESG planting the seeds and setting standards in fighting hackers.

    A pilot scheme for the UK government’s cyber security training initiative has launched in the US, Canada, Australia and New Zealand – meaning British spies are now setting the international standard for fighting hackers.

    The scheme will be run by the Communications-Electronics Security Group (CESG), the information security arm of the GCHQ. It is an extension of the CESG's ongoing UK Certified Professional (CCP) scheme.

    The UK scheme launched in October 2012 and is designed to ensure security professionals meet a quality benchmark set by the CESG, assuring potential hirers of their anti-hacker abilities.

    The scheme ranks professionals at three levels of competency: Practitioner, Senior Practitioner, and Lead Practitioner.

    To date, the scheme has accredited 1,200 UK professionals in a variety of roles, including penetration testers and crypto custodians.

    Penetration testers are hackers companies hire to find holes in their defences. Crypto custodians are professionals that manage companies' use of encryption.

    Encryption is a security technology that scrambles digital information using specialist mathematics. It makes it so only people in possession of a specific unlock key or password can read the encrypted information.

    The pilot international scheme will be limited to security and information risk advisors (SIRA) and IA architects – the people who advise companies on how to protect their data and design their information security systems.

    The new US, Canada, Australia and New Zealand tests will be run by the APMG International examination body and CESG.
    Overcoming the cyber skills gap

    The pilot scheme’s launch is the latest step in the UK and US governments' bid to overcome the reported cyber skills gap. The UK government has warned that there is an ongoing shortage of skilled security professionals.

    UK government spending watchdog the National Audit Office (NAO) estimates the cyber skills gap will last 20 years, costing the nation 27 billion a year. IT skills and certifications body CompTIA reported 45% of of UK businesses are experiencing an "excessive" shortage of IT talent in its "The International Technology Adoption and Workforce Trends Study" in May.

    Read more: GCHQ has expanded its security training scheme to run in the US, Canada, Australia and New Zealand - Business Insider
    It is the same group that validated the efforts of Blackberry. as per business blog 8 days ago.

    The latest guidance–which incidentally also helps organizations comply with requirements for using the government’s high-security Internet alternative, the Public Services Network (PSN)—validates the efforts of BlackBerry and its teams and personnel. The BlackBerry Security Certifications team continues to work with CESG and other government security technical authorities to evolve and increase the security posture of our products, so watch this space for more details of upcoming assurances.
    U.K. Government Releases New BlackBerry Guidance | Inside BlackBerry for Business Blog

    Nice collaboration work with the UK gov't., Blackberry.
    07-29-15 10:43 AM
  22. Soumaila Somtore's Avatar
    sp at $8 wohoo
    07-29-15 10:47 AM
  23. Soumaila Somtore's Avatar
    I hope not!!!!
    Any chance the price will come down under $10?

    Posted via CB10
    bungaboy, zyben, 3MIKE and 3 others like this.
    07-29-15 11:34 AM
  24. Soumaila Somtore's Avatar
    BBRY (sp) In Motion (up up todamoon)
    07-29-15 11:36 AM
  25. zyben's Avatar
    Rock Star Turned Renaissance Man Works Creatively with BlackBerry (Pictures)

    The BBRY Café.  [Formerly: I support BBRY and I buy shares]-1-anderson_bb_duffmckagan_4382.jpg

    Rock Star Turned Renaissance Man Works Creatively with BlackBerry (Pictures) | Inside BlackBerry
    07-29-15 01:30 PM
107,414 ... 34873488348934903491 ...

Similar Threads

  1. Does the Motion have the paratek antenna?
    By Steve Pogue in forum BlackBerry Motion
    Replies: 15
    Last Post: 01-13-18, 01:33 AM
  2. Replies: 11
    Last Post: 11-24-17, 12:06 AM
  3. Will Hub+ work on the new Google Pixelbook?
    By danosman in forum BlackBerry HUB+ Suite
    Replies: 3
    Last Post: 11-02-17, 08:42 AM
  4. BlackBerry highlights the impact of KRACK vulnerability on BlackBerry products
    By CrackBerry News in forum News Discussion
    Replies: 0
    Last Post: 10-30-17, 04:10 PM
  5. Hub and Viber notifications broken
    By LyoobaBerry in forum BlackBerry HUB+ Suite
    Replies: 0
    Last Post: 10-30-17, 03:54 PM

Tags for this Thread